• Odyssey acquired IP and all rights to PRV-002, its lead drug candidate for the treatment of concussions, on March 1, 2021, and has since made notable progress in a strategic move to have the drug approved by the FDA
• Since the acquisition, the company has completed IND enabling studies and all cohorts for Phase I SAD and MAD clinical trials for its lead drug candidate
• In pre-clinical studies PRV-002 has demonstrated equivalent, if not superior neuroprotective effects compared to related neurosteroids, offering proof of reduced behavioral pathology associated with brain injury symptoms, easily crossing the blood-brain barrier to rapidly eliminate swelling, oxidative stress, and inflammation in the brain
• Odyssey’s management is pleased with the progress so far, as the drug advances in its clinical and regulatory pathway and, subsequently, tapping into the concussion treatment market projected to be valued at $8.9 billion by 2027

On March 1, 2021, Odyssey Health (OTC: ODYY), a medical company with a focus on unique, life-saving medical products that offer clinical advantages to unmet clinical needs, acquired intellectual property (“IP”) and all rights to PRV-002, its lead drug candidate for the treatment of concussions (https://ibn.fm/u275p). For a condition affecting millions worldwide, Odyssey recognized a significant unmet medical need and set off to offer a viable solution to the problem. Since the acquisition of the rights, the company has embarked on an aggressive push to develop its program and advance its drug candidate through the regulatory process required by the United States Food and Drug Administration (“FDA”). Its key achievements thus far include successfully completing the processes involved with Investigational New Drug (“IND”) applications, which paved the way for safety studies for the Phase I human clinical trial. Odyssey also successfully developed its nanoparticle drug formulation, in addition to filing a patent application on the unique breath-propelled intranasal delivery device. On September 28, 2022, the company announced the completion of all cohorts for its Phase I Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”) clinical trials for PRV-002, with the drug proving safe and well tolerated throughout the trial. The success of these trials paved the way for the next phase of its clinical study, with the company expressing its satisfaction and optimism for what lies ahead. “I am excited to see that Odyssey’s drug was considered safe throughout the Phase I study,” noted Francis Beaudette, a retired Commanding General of the United States Army Special Operations Command. “Now we can start the important work to determine the efficacy of  PRV-002, a much-needed brain injury solution for the military and beyond,” he added (https://ibn.fm/eIbIn). This announcement followed the formation of a Military Advisory Board within Odyssey that brought on board distinguished military veterans who would assist the company in selecting military sites for the Phase II clinical trial, another critical milestone for the company. According to the World Health Organization (“WHO”), approximately 1.3 million people die annually from head injuries in road crashes. In addition, the Journal of Neurosurgery notes that almost 64-74 million people may suffer from a concussion yearly, with the highest cases in Southeast Asian and Western Pacific regions (https://ibn.fm/Y5Oxz). In the sports sector, nearly 1.6-3.8 million athletes suffer from concussions annually, according to the Brain Injury Research Institute. In addition, 10% of all contact sports athletes sustain concussions yearly, yet there is still no viable treatment option for these conditions. In pre-clinical studies Odyssey’s PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. This fully synthetic, non-naturally occurring neurosteroid has proven to successfully reduce the behavioral pathology associated with brain injury symptoms such as memory impairment, motor/sensory performance, and anxiety. Most notably, it has been shown to easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress, and inflammation in the brain while restoring proper blood flow. The company is currently communicating with the FDA to present findings from its Phase I trial. Phase II trial sites are also being identified, and study design is being created with the site’s medical leadership and the Odyssey Medical Advisors. Odyssey’s management is pleased with the progress, even as it looks forward to FDA approval. It is also looking to tap into the concussion treatment market, projected to be valued at $8.9 billion by 2027, up from $6.9 billion in 2020. For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• The IEA sees EV sales hitting a record in 2022 after doubling in 2021 from 2020, while noting the lack of charging infrastructure as an obstacle for adoption
• Hillcrest Energy has developed a new class of inverters that convert DC output from batteries into AC input used by motors in EVs
• Hillcrest filed a patent application for new tech that eliminates the need for EVs to require and onboard charger, allowing for faster, anywhere charging

During an interview last week with CNBC’s Jim Cramer, Mercedes-Benz CEO Ola Kallenius said he is seeing the market for luxury vehicles progressively turning towards electric vehicles. The Daimler unit has a corporate goal to have an EV version of every model it makes by 2025 and to be all-electric where possible by the end of the decade. The global transition to phase out internal combustion engines is wonderful for Mother Earth, but it is accompanied by a litany of challenges, including a charging conundrum related to strain on an aging and already overworked electricity grid. The good news is that thanks to companies like Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), new technology is becoming available as a solution applicable to EVs and other emerging green energy products. According to the International Energy Agency, EV sales are tracking to hit a record high in 2022 after sales doubled in 2021 from 2020. In its Tracking Clean Energy Progress update, the IEA forecast EV sales to comprise 13% of total light duty vehicle sales globally this year. The agency notes that one hang up in EVs becoming a global phenomenon is lack of charging infrastructure availability. A charging station on every corner is what most people envision as the answer. Others are turning to innovation. Hillcrest, which once was a fossil fuel producer from its asset in Saskatchewan, Canada, has made the change into a clean energy technology company, with its flagship product a single high-efficiency inverter architecture for use throughout electrification ecosystems, from renewable energy generation to EV charging and operation. A new class of inverter technology, Hillcrest’s Silicon Carbide (“SiC”) traction inverter technology converts DC (direct current) output from batteries into AC (alternating current) input used by motors. The unique design enables power applications to utilize higher switching frequencies and realize increased traction motor performance and reliability while operating at higher power levels without sacrificing efficiency. The inverter touches all the key points EV makers are seeking reducing battery size and weight, minimizing overall system complexity, and reducing costs. Hillcrest ran its proof of concept technology through the rigors in internal testing earlier this year, releasing two white papers demonstrating the benefits and durability of its inverters.  It’s first traction inverter commercial prototype is expected by the end of the year. Furthermore, Hillcrest in January filed a patent application for a simplified EV charging solution leveraging its inverter tech to provide universal, backward compatible, bidirectional (“V2X”) charging capabilities. In simpler terms, this solution eliminates the need for EVs to require and onboard charger, allowing for faster, anywhere charging at a wide range of power levels. The company hopes to name a launch partner and for proof-of-concept validation next year. Bringing this technology to market could reshape EV charging infrastructure needs. “An EV capable of accessing AC or DC power across a variety of voltage levels in a wired or wireless environment offers a new level of interoperability not currently available. This could dramatically change the way we think about charging infrastructure and broaden the charging options available to drivers now and in the future,” said Hillcrest CTO Ari Berger. EV powertrains are the low hanging fruit for Hillcrest as it moves into the commercialization stage, but applications abound in new markets where efficient use of power and bidirectional charging are the wave of the future. Usage in wind turbines and solar energy systems can help stabilize the existing electrical grid with the added perk of reducing heat buildup in systems, meaning less wear and tear on parts and reduced stain on thermal management components. For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

• LQwD is focused on creating enterprise-grade infrastructure to drive bitcoin adoption and, develop institutional-grad services supporting the Lightning Network functionality, transaction capabilities, and bring BTC to scale
• LQwD Lightning Network nodes include Canada, France, Japan, England, Japan-Osaka, Australia, Italy, Indonesia, Bahrain, South Africa, South Korea, Sweden, Singapore, Hong Kong, Brazil, Germany, India, Ireland, and US-West
• Currently servicing 17 countries, LQwD plans to increase reach to 24 worldwide by the end of the current quarter
• The global blockchain market was valued at US $4.67 billion in 2021 and is projected to reach US $7.18 billion in 2022, and then US $163.83 billion by 2029

LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF) is a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption and develop institutional-grade services that support the Lightning Network’s functionality, transaction capabilities, user adoption and utility, and scale bitcoin. The company’s platform-as-a-solution (“PaaS”), lqwd.tech enables Lightning Network node hosting and channel management and serves as a Liquidity Service Provider (“LSP”) for merchants – allowing for blockchain transactions worldwide. Blockchain was introduced in 2008 and is a digitally distributed, decentralized, public ledger most notably used with cryptocurrencies – but the technology does not facilitate the transaction times necessary to bring it to scale. The Lightning Network, a layer 2 payment protocol atop the blockchain infrastructure, makes blockchain transactions more efficient with faster settlement times and lower fees. LQwD is leveraging the capabilities of the Lightning Network by establishing worldwide payment nodes that facilitate micropayments in 17 countries, intending to reach 24 by the end of the current quarter. The company released its first node in November 2021 and has since increased its payment capacity to over 30 BTC exceeding 300 channels worldwide. LQwD plans to continue leveraging the network’s potential, adding more nodes, channels, and BTC assets to facilitate payments worldwide. LQwD’s current Lightning Network nodes include Canada, France, Japan, England, Japan-Osaka, Australia, Italy, Indonesia, Bahrain, South Africa, South Korea, Sweden, Singapore, Hong Kong, Brazil, Germany, India, Ireland, and US-West. LQwD’s longest node in operation (almost 12 months old), US-West, has a BTC capacity of 6.11051221 (US $117,552.81) and 112 active channels. The node has been connected to 111 additional nodes to facilitate faster payment settlement times with lower fees. The active nodes (and future nodes) will help further the company’s goals to scale the Lightning Network for Bitcoin advancement. Recent updates from 1ml.com, a blockchain explorer offering the ability to search the Lightning Network’s node activity, reported that the Lightning Network had surpassed previous records, reaching a capacity of 4800 BTC (equivalent to approximately US $92 million). The top three countries include the United States (2586 BTC), Germany (370 BTC), and Canada (139 BTC) (https://ibn.fm/TYx6q). The adoption of digital ledger technology by companies looking to secure end-user financial data and identity is driven by the necessity for cross-border transactions, expedient clearing and settlement times, trade financial platforms, digital identity verification, and credit reporting are gaining traction across the market. The global blockchain market was valued at US $4.67 billion in 2021 and is projected to reach US $7.18 billion in 2022. By 2029, growing at a CAGR of 56.3%, the market is expected to reach US $163.83 billion (https://ibn.fm/Cczkb). LQwD plans to leverage its position as a public company to enhance trust in its products and services, easily access capital through the markets, leverage stock as currency for acquisitions, and attract/retain top industry talent. The strategy to scale the market includes offering its PaaS for Lightning Network nodes and payment channels, providing LSP services for merchants, and accumulating Bitcoin as a treasury reserve asset for staking and liquidity. For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• Data Protection has increasingly become a focus around the globe, with the United States and Europe recently agreeing to implement a joint data privacy framework
• With one small company said to be successfully hacked every 19 seconds, losses attributed to data breaches in the United Kingdom alone amount to over £4 billion per annum
• Reklaim has centred its business model around enabling users to reclaim their data, delete it or in its stead, monetize it
• The company recently entered a non-binding letter of intent to purchase US-based Multimedia Lists to expand its top-line revenue and profitability further

In 2004, Philip Cummings pleaded guilty to one of the most significant identity theft cases in the United States. Cummings worked at a desk job at Teledata Communications, Inc. in Long Island, New York, helping companies run routine credit checks. On the day he resigned, Cummings packed up his desk – along with the passwords of 33,000 of the company’s clients. Cummings would go on to sell the sensitive data to criminals who would use it to drain bank accounts and open new lines of credit, with total losses pegged by the Government at upwards of $100 million (https://ibn.fm/KfBlo). While enormous, the scale of losses generated by Cummings’ actions is increasingly trivial in today’s online world. In the United Kingdom alone, one small business is hacked every 19 seconds, with data breaches driven by identity theft reportedly costing the nation over £4 billion in losses every year (https://ibn.fm/cJEGS). It is this growing phenomenon that companies like Reklaim (TSX.V: MYID) (OTCQB: MYIDF) seek to tackle. Reklaim’s creation was a by-product of the ongoing evolution of data privacy and its impact on consumers and companies. The company’s revolutionary system allows consumers to log in to their platform and confirm their identity, unlocking data collected on them that has been bought and sold for years without their explicit consent. At that point, consumers can take control of their data and, if they choose, receive compensation for its use. With consent secured, Reklaim offers the data to Fortune 500 brands, platforms, and data companies, and when sold, the consumer is compensated a fractional share of the revenue. The company also has a privacy SaaS subscription service for privacy-conscious consumers interested in knowing when their data has been breached and who would like to reduce the amount of data leaking from their devices (https://ibn.fm/6NcJi). While data protection is not a novel development – the European Union published its initial data protection rules as far back as 1995 – the use of customer data has become an increasingly integral part of many companies’ commercial operations in recent years. The ongoing move towards restoring customer data privacy and the occasional lack of data availability has resulted in many unintended consequences across businesses. For instance, Meta (formerly Facebook) recently guided that it expected 2022 revenues to decline by $10 billion because of Apple’s changes to restrict user data collection across external applications (https://ibn.fm/cRcC0). Meanwhile, the popular navigation app Waze became less effective in one of the more unexpected outcomes of the COVID pandemic. With fewer drivers on the road during widespread lockdowns, it no longer benefitted from a steady flow of data to feed into its algorithms (https://ibn.fm/aGehT). Seeking to capitalize on the increased global emphasis on data privacy, the desire from consumers to monetize their personal information, as well as growing commercial demands to access consumer-generated insights, Reklaim recently revealed that it had entered a non-binding letter of intent to purchase the assets of US-based data broker, Multimedia Lists (“MML”). The transaction, which is expected to double the revenue of the amalgamated entity post-acquisition immediately, will entail a purchase price determined as a multiple of MML’s EBITDA and will also include a performance earn-out over a four-year term. “MML has several Fortune 500 clients that complement the existing clients and distribution of Reklaim. As privacy legislation and technology changes put the onus on data companies to ensure that clients’ data is compliant, partnering with Reklaim will help MML retain and grow its client base. As we have previously communicated to the market, we have identified a unique opportunity to amalgamate data companies that lack the tools to maintain consent with consumers, and we are excited to accelerate this strategy over the coming quarters,” said Reklaim CEO Neil Sweeney regarding the potential acquisition (https://ibn.fm/wUzCx). For more information, visit the company’s website at www.ReklaimYours.com. NOTE TO INVESTORS: The latest news and updates relating to MYIDF are available in the company’s newsroom at https://ibn.fm/MYIDF

• Google recently announced the closure of its Google Stadia gaming business, a decision which may have partly been underpinned by the dearth of new gaming titles available on the platform
• Content has remained a crucial driver of success within the iGaming industry, a factor which Golden Matrix Group have sought to cater to
• Through their proprietary GM-X turnkey solution, the company provides its licensing partners with access to upward of 10,000 games drawn from over 25 gaming studios

On November 19, 2019, Google made an announcement that was set to potentially change the face of the gaming universe as we know it. Google was set to launch their Google Stadia cloud-based gaming platform, a revolutionary system which bypassed the erstwhile console gaming industry, rather allowing gamers to access their games via streaming across a host of compatible TVs, computers, and mobile devices. However, and whilst the idea was game changing in nature, the execution lagged far behind. Google Stadia recently announced that it would officially shut up shop on January 18, 2023, bringing a close to the internet giant’s push into online gaming (https://ibn.fm/7Z90p). However, a key rationale which may have led to the early closure of Google Stadia may also be the same factor dictating the potential failure or success of the iGaming business – content. A key issue pinpointed as the reason behind Google Stadia’s relative lack of success was the gaming company’s economic model: subscribers to Stadia Pro would be given a handful of games each month that they could access for as long as they had a subscription – similar to PlayStation Plus – whereas the majority of games required a separate purchase. As a result, gamers expecting to benefit from reams of available games were forced to deal with relatively limited selections. The situation was only further exacerbated only 14 months post the launch of the gaming system, when Google decided to shutter its internal game development studio; the company would opt to switch their focus towards building out a gaming content aggregator platform rather than an original content distributor as originally envisioned (https://ibn.fm/kEQky). Whilst Google’s exit from the online gaming space inevitable captured the headlines, it is an iteration of a broader trend affecting the iGaming space – one which has seen new platforms opt towards adopting a white-labelled gaming solution whilst directing their efforts and resources towards marketing and promotional endeavours. Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, has sought in turn to carve out its own niche within the content aggregation and B2B iGaming space in a move designed to capitalize on the ongoing industry shift. Golden Matrix Group purveys its services to the B2B gaming industry through its proprietary GM-X turnkey solution, a complete software package designed to support online gaming businesses. The white-labelled service provided third party gaming platforms with access to GMGI’s expansive portfolio of over 10,000 games, ranging from online slots, casino table games, live operator games, and more drawn from Golden Matrix Group’s partnership with more than 25 gaming studios. The iGaming space is forecast to deliver record growth in coming years; a recent study by VIXIO GamblingCompliance projected that the combined online gaming sectors within the US could triple in size over the next five years, reaching an annual value of $24.3 billion as of 2026. Considering that growth, a roundtable was recently carrying out, uniting a number of the most influential figures within today’s iGaming marketplace to discuss whether content aggregation remained the most effective manner in which to distribute content within the industry. Whilst roundtable participants touched upon the rise of regulations and compliance within the sector as well as the growing need for content providers to adhere to these changing requirements, they did reaffirm their view on the continued success of the content aggregation model. During the roundtable, Peter Causley, CEO of Lightning Box Games elaborated on the topic: “Content is, of course, still king, however in Europe and the UK at least volume can be considered the queen. This sudden shift to focus on the volume of game releases is in part to combat their shrinking market shares, due to increasing competition, and dwindling revenues from more heavily regulated markets found in the UK and Germany” (https://ibn.fm/B12lE). A key reason speculated as leading to the ultimate demise of the Google Stadia gaming initiative related to the platform’s relative lack of content – a phenomenon spurred on by the closure of its internal gaming studio as well as the dearth of new games on its platform. With over 10,000 games available through its proprietary GM-X gaming solution, Golden Matrix Group for one, has far surpassed its industry competitors in terms of the breadth and dizzying array of content at its disposal. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

• Lexaria Bioscience, a global innovator in drug delivery technology, has developed a potential treatment for hypertension using the company’s patented DehydraTECH(TM) platform, now shown in several human studies to reduce blood pressure and arterial stiffness
• Lexaria’s antihypertensive drug development program comes at a time when researchers are documenting poor control of hypertension among both men and women, partly due to suboptimal adherence to existing antihypertension medication
• Reasons advanced for the suboptimal adherence include lack of awareness or treatment, increased number of prescribed medications, and major adverse effects of the prescribed drugs
• Lexaria has so far shown that its DehydraTECH-CBD is not only effective but also well tolerated and is planning to undertake registered clinical trials in pursuit of the FDA’s approval of the drug candidate

A recent research article published in the Journal of the American Heart Association (“AHA”) unearths data that suggests poorly controlled hypertension among both men and women (https://ibn.fm/oy2TN), a problem global innovator Lexaria Bioscience (NASDAQ: LEXX) is keen on solving. The researchers, who sought to describe gender-differential disease patterns and results of more than 20.6 million emergency department encounters in the United States from 2016 to 2018, made several observations. Firstly, most ED cardiovascular (“CVD”) visits in the sample were due to hypertensive diseases. Secondly, essential hypertension, which is high blood pressure not resulting from other maladies, was the most common CVD diagnosis in women and second most common in men (https://ibn.fm/2b9jQ). Moreover, the article notes, “Attendances for essential hypertension were more common in women, which may reflect higher rate of preexisting hypertension in women (76.6% vs. 74.4%). These findings may also reflect poorer control of hypertension or poorer access to primary care in women… Further supporting these suppositions, in our sample, although men were less likely to present to the ED with essential hypertension, they were slightly more likely to present with long-term consequences of hypertension-related end-organ damage (hypertensive heart or kidney disease) and were more likely to die following such presentations, suggesting longer duration of exposure to poorly controlled hypertension than women.” This recent study is one of the latest in a series of research works on uncontrolled hypertension that date back to the 20th century. In a scholarly article published in 2005 in the AHA Journal, for example, researchers observed a high prevalence of uncontrolled hypertension that suggested a significant number of CVD events could be prevented by improved blood pressure control. “The benefits of pharmacological treatment for [hypertensive] patients are well established. Meta-analysis of randomized placebo-controlled trials indicate that antihypertensive therapy reduces the risk of stroke by approximately 30%, coronary heart disease by 10-20%, congestive heart failure by 40-50%, and total mortality by 10%,” the 2005 research article continues (https://ibn.fm/9WAMD). Several other studies have put forth reasons that are thought to cause suboptimal adherence, leading to poor control. These reasons include the lack of awareness or treatment, an increased number of antihypertensive drugs, and major adverse effects, just to mention a few (https://ibn.fm/46bPk). As this happens, hypertension remains the leading cause of noncommunicable disease deaths globally, raising concerns that have caught the attention of Lexaria, a company developing a potential hypertension treatment with little to no side effects. The treatment is created by processing cannabidiol (“CBD”) using the company’s patented DehydraTECH(TM) drug delivery technology, which has been shown to substantially increase the bioavailability of active pharmaceutical ingredients (“APIs”). In human studies, Lexaria has shown that DehydraTECH-CBD not only increases the amount of CBD in the blood by as much as 317% but also reduces blood pressure and arterial stiffness. To put these findings into a more comprehensive context, the company’s 24-person human clinical study, christened HYPER-H21-1, evidenced a rapid and sustained drop in blood pressure. The second study, HYPER-H21-2, a 16-person HCS, showed up to a 23% reduction in overnight blood pressure as well as reduced arterial stiffness, while the third study, HYPER-H21-3, evidenced attenuated pulmonary artery systolic pressure. What the three studies had in common was that no serious adverse events were reported, suggesting that DehydraTECH-CBD is well tolerated (https://ibn.fm/BZWuX). To further confirm this fact, Lexaria is working toward a planned Phase I(b) trial, expected to commence following the filing of an Investigational New Drug (“IND”) application and the fulfillment of other regulatory requirements. According to the company, the IND-enabling program is currently underway and is expected to be completed later this year or early next year (https://ibn.fm/dOnXv). Lexaria hopes to prove, through registered clinical trials, that its DehydraTECH-CBD formulation has an acceptable safety and tolerability profile and that it is effective against hypertension. The proof could potentially influence the registration of DehydraTECH-CBD as the second FDA-approved CBD drug, offering a reprieve to millions of hypertension patients who do not have their condition under control because they receive numerous antihypertensive drugs or are unwilling to suffer through these medications’ adverse side effects. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Colombia and the United States have both recently exhibited new openness to the possibility of decriminalizing adult recreational cannabis use through legislative change
• Cannabis supplier Flora Growth cultivates its product at a key Colombian farm and provides it to international markets, and may see additional opportunities arise as cannabis policies advance in the two countries
• Flora Growth recently announced completion of its first shipments of high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD isolate supplied to its market in the United States
• The company also recently reported a 604 percent YOY increase in revenues during the H1 reporting period, with a 547 percent gross profit increase during that period

Cannabis may be approaching a new watershed moment as Colombia pushes for national legalization of adult-use marijuana and the United States’ government undertakes long-anticipated discussion of whether to change the drug’s classification. The nearly unanimous approval of legislation to legalize and regulate adult-use cannabis by an initial committee reviewing bills in Colombia’s legislature, coupled with the president’s criticisms of decades-long prohibitionist policies and regulatory advances made by his predecessor, position the fertile country with a storied history on the front lines of the global war on drugs to become a major legal producer of cannabis and its derivatives (https://ibn.fm/nuBv7). In the United States, the President recently issued executive pardons to criminals convicted of marijuana possession in federal cases and asked federal health and law enforcement agencies to take a fresh look at the possibility of ending marijuana’s classification as an illicit substance, creating energy for cannabis stocks in the country (https://ibn.fm/2CkcE). International cannabis company Flora Growth (NASDAQ: FLGC) is headquartered in Fort Lauderdale, Florida but operates its cultivation from a 100-hectare (about 247-acre) licensed farming facility in northern Colombia where it develops cannabis products and then ships them into international markets or to its GMP-certified facility in the nation’s capital for transformation into consumer ready goods. The company’s NASDAQ listing precludes it from participating in the U.S. domestic market for adult-use cannabis at present, where marijuana has enjoyed some approval on a state-by-state basis despite the federal prohibitions. But the continually developing approach to recreational cannabis use in Colombia and the United States portends possible new opportunities for the company beyond its current low-cost operation supplying THC and CBD flower and derivatives to international markets and the CBD it provides to its own product supply chain. “We are proud to help increase access to safe, legal CBD and THC to consumers all over the globe,” Flora Growth Chairman and CEO Luis Merchan stated last month after the company announced completion of its first exports to of high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD isolate supplied to its market in the United States (https://ibn.fm/bFVa2). Investors have taken a wary approach to cannabis stocks amid ongoing global economic turmoil continuing beyond the immediate impact of the COVID pandemic. But financial data reported by Flora Growth indicates the company has reason for optimism that its strategic advances are taking it in the right direction. Flora’s most recent revenue report states that revenues increased 604 percent increase YOY during the H1 period and 117 percent of the previous half-year report (https://ibn.fm/SK2gD). “Our gross profit increased 547 percent over that same period last year and we expect our revenues for the full year to grow between 300 and 400 percent for … 2022,” Merchan said as part of the management’s analysis of the results. “Despite (COVID-related challenges and economic uncertainty), Flora business units continue to improve their performance.” For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• Net-Zero initiatives critical to combatting climate change according to global policymakers, worldwide coalition formed to cut greenhouse gas emissions to as close to zero as possible by 2050
• Transition from fossil hydrocarbon-based energy systems requires massive reconfiguration of energy systems
• GeoSolar’s SmartGreen(TM) Home system provides complete total-home energy “makeover” comprising solar panels, geothermal ground loops, LED lighting, upgraded insulation, energy-efficient windows
• GeoSolar conducting Regulation A+ capital raise with minimum $300 investment

Transitioning to “Net-Zero” – a concept first promoted at the United Nations Climate Change Conference (COP21) – is critical to combatting the effects of climate change, according to global policymakers (https://ibn.fm/dMgSK). Since then, a coalition representing major cities, businesses, investors, and educational institutions has formed to promote initiatives aiming to achieve net-zero carbon emissions by 2050. GeoSolar Technologies (“GST”) is a Colorado-based climate technology company dedicated to Net-Zero initiatives by helping residents and businesses reduce carbon emissions and achieve energy independence. The company’s SmartGreen(TM) Home systems harness the power of the sun and earth to heat and cool buildings, charge electric vehicles, and run electric appliances while purifying the air and maximizing energy efficiency. “Much technology has to be developed, not just on emissions, but on sequestration and all the other technologies we’re talking about to get to zero carbon,” said John Anderson, President of The National Academies of Sciences, Engineering, and Medicine in a recent interview (https://ibn.fm/RdSff). “The transition from our current fossil hydrocarbon-based energy system to a net-zero carbon future is going to require a massive reconfiguration of our entire global energy system.” With an eye on global Net-Zero goals, GeoSolar ’s technology empowers building owners to act locally by leveraging a mix of renewable energy sources. The company’s patent pending SmartGreen(TM) Home system is a total building energy “makeover” that comprises solar panels and geothermal ground loops to maintain temperature and power household appliances and electric vehicles. “The first priority is to deploy known technologies that have been developed over the past 20 or 30 years to address easy-to-decarbonize processes,” continued Anderson. “So, what’s easy to decarbonize? HVAC in homes, local transportation around cities, electric vehicles, household appliances, and so on, because we have various solutions already available.” SmartGreen(TM) builds upon those existing solutions and takes them further with additional measures that include tightening the building envelope and upgrading insulation, windows, and lighting systems. With options to build systems into new construction or existing buildings, SmartGreen(TM) helps property owners cut CO2 emissions by up to 8 tons per year while reducing or even eliminating energy bills (https://ibn.fm/TeYJY). GeoSolar aims to take SmartGreen(TM) mainstream by marketing the system to 120 million homes across the United States. The company is currently conducting a Regulation A+ capital raise that allows the public to invest in a carbon-free future for as little as $300 (https://ibn.fm/ZUaLw). For more information on GeoSolar’s Regulation A+ capital raise, please visit www.manhattanstreetcapital.com/geosolar-technologies-inc. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Odyssey Health is a medical company developing unique, life-saving products that address unmet clinical needs such as concussion, which does not have an FDA-approved therapeutic
• The company has developed PRV-002, a neurosteroid for the treatment of concussion, and an intranasal delivery device that delivers the drug into the upper chamber of the nasal cavity for onward travel into the brain
• Odyssey’s just concluded Phase I clinical trial shows that PRV-002 is safe and well tolerated
• The findings from the study are likely to benefit the military as well as the NFL, given military personnel and players frequently suffer concussions

In 2002, NFL Pro Hall of Famer and former center Michael Lewis Webster became the first ex-NFL player to be diagnosed through autopsy with chronic traumatic encephalopathy (“CTE”), a degenerative brain disorder believed to be caused by repeated concussions (https://ibn.fm/ZxgeE). Since then, doctors, the NFL in general, and medical companies like Odyssey Health (OTC: ODYY) have learned a lot about concussions and CTE. On its part, the NFL has progressively implemented a raft of player safety policies aimed at protecting players. Despite the spate of safety policies, which include fines and suspensions to players, football remains a dangerous sport that sees players with massive physiques collide with one another. It is no question that this physicality can cause damage to the brain and body, and a recent incident, which has elicited widespread criticism and uproar from fans and coaches alike, demonstrates the danger posed. In the last week of September – week three, the football community watched in horror as Dolphins Quarterback Tua Tagovoiloa sustained yet another concussion just a week after he had been taken out of a game and probed for a possible concussion, with criticism pouring as to why the Dolphins coaching staff had included him in the day’s playing roster in the first place. The criticism and concern around concussions are valid. As of 2017, over 100 ex-NFL players had received postmortem diagnoses of CTE (https://ibn.fm/epRtP). In addition, scores of players have been forced into early retirement after they suffered a concussion (https://ibn.fm/V956u). In understanding the dangers, coaches like the New England Patriots’ Bill Belichick have learned the telltale signs of unwell players. Belichick has even had to take players out of games because he suspected they had sustained a concussion, sometimes going against medical staff who had cleared them to play (https://ibn.fm/wMvbj). But an intervention that could potentially improve the efficacy of the NFL’s concussion protocol and prevent the development of concussion symptoms by reducing brain swelling, inflammation, and oxidative stress as well as normalizing blood flow to the brain is in the works. The intervention being developed by Odyssey as a potential treatment for concussion is a novel non-naturally occurring neurosteroid by the name PRV-002 delivered through the company’s patent-pending breath-propelled intranasal drug delivery device. Odyssey believes the drug candidate could boost the chances of successful recovery for concussed patients by taking advantage of the drug-device combination’s ability to facilitate quick administration of PRV-002. A dry powder that does not require special handling or refrigeration, PRV-002 can sit on the sidelines of football games, allowing medical staff to administer it immediately if they suspect a player has sustained a concussion. According to Odyssey, the intranasal delivery device delivers the dry powder into the upper chamber of the nasal cavity without being swallowed or inhaled. The drug then travels along the cranial nerve toward the brain, where it crosses the blood-brain barrier within 5 minutes of administration and spreads throughout the brain within 30 minutes, reversing the effects of a concussion. The drug candidate was recently administered to healthy volunteers as part of a just-concluded Phase I clinical trial, which demonstrated that PRV-002 was safe and well tolerated (https://ibn.fm/JWh5R). Next, Odyssey is planning to undertake a Phase II study that will investigate PRV-002’s efficacy in concussed patients. The company will initially conduct its evaluations in select military training camps, where military personnel frequently sustain concussions during training. Eventually, however, Odyssey wishes to move into athletic models working in conjunction with the National Collegiate Athletic Association’s (“NCAA”) medical centers, possibly by 2023 (https://ibn.fm/e3bO7). The findings from the upcoming study are likely to benefit military personnel and NFL players who are highly vulnerable to concussions. According to the latest data from the Military Health System, for example, 377,425 members of the U.S. Armed Forces had suffered a concussion (also known as mild traumatic brain injury) between 2000 and the first quarter of this year (https://ibn.fm/G8zAp). On the other hand, NFL’s injury data shows that in each of the five years to 2019, the total number of concussions suffered during practice and gameplay was well above 200. And although the figures dropped in 2020 and 2021 due to COVID-19 and a change in the NFL season structure, respectively, over 170 concussions were reported in each of these seasons (https://ibn.fm/6sYAI). For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• The global electric vehicle fleet will rise to between 140-240mn cars by 2030, resulting in over 7TW of battery capacity
• The growth of the EV industry as well as the rise in renewable power sources has led to rising interest in vehicle-to-grid technology
• Vehicle-to-grid technology allows for an electric vehicle to engage in bidirectional charging, effectively allowing a vehicle to drive excess power back into the grid
• Through their revolutionary enhanced powertrain solution, Hillcrest Energy Technologies are seeking to pioneer the way towards efficient bidirectional charging

The global electric vehicle population is set to swell to between 140 and 240 million electric battery-powered vehicles by 2030; in effect, it means we will have at least 140 million energy storage devices on wheels with an aggregated storage capacity of 7TWh (terawatt hours) on the road over the course of the next decade (https://ibn.fm/QtuHz). To put that into perspective, a global electric vehicle fleet of 140 million vehicles would effectively be able to power the United States’ annual electricity consumption twice over on a single charge. By some estimates, it could lead electricity consumption to rise by as much as 38 percent within the U.S. by 2050, a phenomenon that has thrust the vehicle-to-grid technology sector into the global spotlight. Vehicle-to-grid technology enables energy to be pushed back to the power grid from the battery of an electric car; with electric vehicle-to-grid technology – also known as car-to-grid – a car battery can be charged and discharged based on different signals, such as energy production or consumption nearby. With the global vehicle-to-grid technology market size forecast to grow from a value of $1.77 billion in 2022 to approximately $17.43 billion by 2027, a CAGR of more than 48 percent over the period in question, Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), a clean technology company developing transformative power conversion technologies has sought to introduce its proprietary solution into the mix. Hillcrest Energy Technologies has filed a patent for an enhanced powertrain solution, which offers the potential to simplify EV charging and redefine how the industry envisions charging infrastructure. The company believes the most exciting benefits of the enhanced powertrain solution are the ability to eliminate the onboard charger and booster from an EV, as well as faster, anywhere charging including direct DC, wireless, and bidirectional charging across current and future power levels. Global energy grids are increasingly turning towards renewable energy to achieve global decarbonisation and net-zero targets. However, a key issue affecting the deployment of renewable energy sources relates to the storage of energy. While fossil fuels can be seen as a form of energy storage, given they release energy as they are burned, wind and solar energy produce power during intermittent intervals, thus necessitating new ways in which to balance and store energy. While some sources of renewable energy are cheaper in terms of electricity generation costs than conventional fossil fuels, surveys carried out by EIA have revealed the costs of installing and operating large-scale battery storage systems in the United States have declined in recent years. In 2019, the average battery energy storage capital costs $589 per kilowatthour (“kWh”), while battery storage costs fell by 72% between 2015 and 2019, a 27% per year rate of decline. The lowering costs give facilities more space to store energy which increases the duration of battery systems while in use. The price decline in energy storage has expanded beyond batteries into other technologies like hydrogen, compressed air, etc (https://ibn.fm/DY5Fe). This phenomenon in turn has driven ever-increasing interest into vehicle-to-grid technology, with electric vehicle batteries being the most cost-efficient form of energy storage given that they require no additional investments in hardware. While an electric vehicle battery will absorb electricity until it is fully charged, the ability for a vehicle to engage in ‘bidirectional’ charging would effectively allow for the vehicle-to-grid charging device to absorb any excess electricity from the car battery and push it back to the grid, where it continues its journey to the nearest location where it’s needed. The International Energy Agency (“IEA”) has predicted that global renewable electricity capacity will rise by more than 60 percent from 2020 levels to over 4,800 GW – equivalent to the current total global power capacity of fossil fuels and nuclear combined (https://ibn.fm/ZouUI). In fact, renewables are set to account for almost 95 percent of the increase in global power capacity through 2026. With the combined production plus battery storage costs for renewable sources yet to reach parity with conventional fuel sources, electric vehicle batteries may hold the answer for the next step of the global journey towards Net Zero. With its soon-to-be-commercialized enhanced powertrain solution, Hillcrest Energy Technologies is ready for the next phase in the global energy revolution. For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF